Full Press Release Details
Cerulean Reports Second Quarter 2014
Corporate Highlights and Financial Results
CAMBRIDGE, Mass. August 12, 2014 Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting , today provided an
update on corporate activities during the quarter ended June 30, 2014.
In the second quarter, Cerulean became a public company, raising money
to conduct clinical trials of our first two platform-generated product candidates, said Oliver S. Fetzer, Ph.D., President and Chief Executive Officer of Cerulean. Our lead candidate, CRLX101, has shown activity in multiple tumor-types,
as both monotherapy and in combination with other cancer treatments, and it has been well tolerated in more than 200 patients to date. We are conducting CRLX101 trials in three tumor types: relapsed renal cell carcinoma, or RCC, relapsed ovarian
cancer, and non-metastatic rectal cancer.
Our second candidate, CRLX301, is expected to enter the clinic by year-end, continued
Dr. Fetzer. Both of our candidates are nanoparticle-drug conjugates, or NDCs, that are designed to selectively attack tumor cells, reduce toxicity by sparing the body s normal cells, and enable therapeutic combinations.
Dr. Fetzer also summarized anticipated timelines for the announcement of clinical results. We anticipate announcing data from two ongoing
single-arm CRLX101 trials in the first quarter of 2015, data from an ongoing randomized CRLX101 trial by the end of 2015, and data from a planned Phase 1 CRLX301 trial by the end of 2015.
Second Quarter 2014 Corporate Highlights
Key Subsequent Event
Anticipated Upcoming Milestones
During the remainder of
2014 and in 2015, Cerulean plans to:
Brief Financial Summary
As of June 30, 2014, Cerulean had cash and cash equivalents of $64.3 million. Cerulean estimates that its current cash and cash equivalents will allow it
to fund several ongoing single-arm clinical trials of CRLX101, an ongoing randomized Phase 2 clinical trial of CRLX101, and a planned Phase 1 trial of CRLX301.
On August 12, 2014, Cerulean filed its financial results for the second quarter ended June 30, 2014, as part of its Quarterly Report on Form 10-Q,
which can be accessed via the following links: http://ir.ceruleanrx.com/sec.cfm or www.sec.gov.
CRLX101 is a dynamically tumor-targeted nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload,
camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and hypoxia-inducible factor-1
(HIF-1 ), which research suggests is a master regulator of cancer cell survival mechanisms thought to promote drug and radiation resistance. CRLX101 has shown activity in late-stage disease in three
different tumor types, both as monotherapy and in combination with Avastin . CRLX101 is currently in Phase 2 clinical development and has been dosed in more than 200 patients.
About Cerulean s Dynamic Tumor Targeting Platform
Cerulean s Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments. We believe our NDCs
concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the leaky vasculature present in tumors but are too large to pass through the wall of healthy blood vessels.
Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of
NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body s normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of
which aim to unlock the power of combination therapy. www.ceruleanrx.com
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product
candidates, and other statements containing the words anticipate, believe, continue, could, estimate, expect, intend, may, plan,
potential, predict, project, should, target, would, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing
of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of
the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the
Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any
forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update
any forward-looking statements included in this press release.
Avastin is a trademark of
MacDougall Biomedical Communications